Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current trends in large cell lymphoma.

R I Fisher1, P Shah

  • 1Division of Hematology/Oncology, James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA.

Leukemia
|September 27, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of indoor ventilation on TB transmission risk: implications of climate change.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2026
Same author

Immune checkpoint blockade in locally advanced rectal cancer with deficient DNA mismatch repair: retrospective multicenter experience.

ESMO open·2026
Same author

Bridging the Gap: Managing Hypertension in Indian Patients with Metabolic Syndrome.

The Journal of the Association of Physicians of India..·2025
Same author

Prevalence Survey of Antimicrobial Use among Admitted Patients in Tertiary Care hospital: An observational study.

Kathmandu University medical journal (KUMJ)·2025
Same author

Adverse events among early caregivers' COVID-19 vaccination correlated inversely with intention to vaccinate their children.

Vaccine·2025
Same author

Global airway disease: mepolizumab simultaneously improves outcomes in severe CRSwNP and asthma.

Rhinology·2024
Same journal

Redefining light-chain smoldering multiple myeloma: prevalence and progression risk.

Leukemia·2026
Same journal

Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II.

Leukemia·2026
Same journal

Retroperitoneal bulk predicts chylothorax in follicular lymphoma-control requires systemic response.

Leukemia·2026
Same journal

Linperlisib enhances MUC1-Tn CAR T cell efficacy by inhibiting EGR1/DUSP2 axis to prevent CAR T cell exhaustion.

Leukemia·2026
Same journal

CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia.

Leukemia·2026
Same journal

Single-cell architecture of purinergic signaling in human cord blood hematopoietic stem and progenitor cells.

Leukemia·2026
See all related articles

Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy offers a standard treatment for aggressive non-Hodgkin's lymphoma (NHL), but survival rates remain suboptimal. Novel strategies and molecular markers are being explored to improve outcomes for these patients.

Area of Science:

  • Oncology
  • Hematology
  • Pharmacology

Background:

  • Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) has been the standard of care for aggressive non-Hodgkin's lymphoma (NHL) for a decade.
  • CHOP offers comparable efficacy to other regimens with lower toxicity and cost.
  • However, CHOP cures only 40-45% of patients, indicating a need for improved therapies.

Purpose of the Study:

  • To review current and emerging treatment strategies for aggressive non-Hodgkin's lymphoma (NHL).
  • To discuss the role of novel agents, dose escalation, and resistance-modifying approaches.
  • To explore the potential of molecular markers and prognostic indices in refining treatment decisions.

Main Methods:

  • Review of existing literature on CHOP chemotherapy and novel therapeutic strategies for NHL.

Related Experiment Videos

  • Analysis of studies incorporating Rituximab, dose escalation with G-CSF, and infusional regimens.
  • Examination of the impact of the International Prognostic Factor index (IPI) and molecular markers on patient outcomes.

    • Main Results:

    • While CHOP is a cost-effective standard, cure rates are limited.
    • New strategies like adding Rituximab, dose escalation, and novel agents show promise.
    • Molecular markers are emerging as important tools for profiling NHL behavior and identifying high-risk patients.

    Conclusions:

    • Significant opportunities exist to improve survival in aggressive non-Hodgkin's lymphoma.
    • Personalized treatment approaches, guided by prognostic factors and molecular profiling, are crucial.
    • Further research into novel therapeutic combinations and targeted therapies is warranted.